LianBio Announces China National Medical Products Administration (NMPA) Acceptance with Priority Review of New Drug Application for Mavacamten for the Treatment of Patients with Obstructive Hypertrophic Cardiomyopathy

April 21, 2023

https://www.globenewswire.com/news-release/2023/04/21/2651891/0/en/LianBio-Announces-China-National-Medical-Products-Administration-NMPA-Acceptance-with-Priority-Review-of-New-Drug-Application-for-Mavacamten-for-the-Treatment-of-Patients-with-Obst.html

SHANGHAI, China and PRINCETON, N.J., April 21, 2023 (GLOBE NEWSWIRE) — LianBio (Nasdaq:LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, today announced that China’s National Medical Products Administration (NMPA) has accepted with priority review the New Drug Application (NDA) for mavacamten for the treatment of symptomatic obstructive hypertrophic cardiomyopathy (oHCM) in adults.

Read more at globenewswire.com

Related news for (LIAN)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.